BAXTER INTERNATIONAL, INC.; INC.;BAXTER HEALTHCARE S.A.;BAXTER INTERNATIONAL
发明人:
SCHNECKER, KURT,HAIDWEGER, EVA,TURECEK, PETER
申请号：
NZ59270409
公开号：
NZ592704A
申请日:
2009.10.21
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
A stable lyophilized pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF； (b) one or more buffering agents； (c) one or more amino acids； (d) one or more stabilizing agents； and (e) one or more surfactants； said rVWF comprising a polypeptide selected from the group consisting of: a) the amino acid sequence set out in SEQ ID NO: 3； b) a biologically active analog, fragment or variant of a)； c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1； d) a biologically active analog, fragment or variant of c)； and e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions； said buffer is comprising of a pH buffering agent in a range of about 0.1 mM to about 500 mM and said pH is in a range of about 2.0 to about 12.0； said amino acid is at a concentration of about 1 to about 500 mM； said stabilizing agent is at a concentration of about 0.1 to about 1000 mM； and said surfactant is at a concentration of about 0.01 g/L to about 0.5 g/L.
